Literature DB >> 16287686

Emerging diseases: measles.

Martin O Ota1, William J Moss, Diane E Griffin.   

Abstract

High vaccination coverage rates and the administration of a second dose of measles vaccine have resulted in a significant decline in the incidence of measles and neurologic diseases due to measles in many countries. However, intermittent outbreaks of measles still occur even in countries with excellent vaccination coverage, suggesting the existence of high rates of measles virus introduction from endemic regions and/or waning of vaccine-induced immunity. Strategies to sustain high levels of global immunity to measles virus by increasing vaccine coverage with routine and supplementary vaccination campaigns must be supported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16287686     DOI: 10.1080/13550280591002441

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  89 in total

1.  Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage.

Authors:  C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Measles mortality reduction--West Africa, 1996-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-01-23       Impact factor: 17.586

3.  Population-based study of measles and measles immunization in human immunodeficiency virus-infected children.

Authors:  P Palumbo; L Hoyt; K Demasio; J Oleske; E Connor
Journal:  Pediatr Infect Dis J       Date:  1992-12       Impact factor: 2.129

4.  Serologic response of children to in-activated measles vaccine.

Authors:  C H CARTER; T J CONWAY; D CORNFELD; D G IEZZONI; C H KEMPE; C MOSCOVICI; L W RAUH; A J VIGNEC; J WARREN
Journal:  JAMA       Date:  1962-03-17       Impact factor: 56.272

5.  Severe measles in the tropics. I.

Authors:  D Morley
Journal:  Br Med J       Date:  1969-02-01

6.  Development of antibody to measles virus polypeptides during complicated and uncomplicated measles virus infections.

Authors:  M Graves; D E Griffin; R T Johnson; R L Hirsch; I L de Soriano; S Roedenbeck; A Vaisberg
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

7.  The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children.

Authors:  Bracha Rager-Zisman; Elina Bazarsky; Agneta Skibin; Shlomo Chamney; Ilana Belmaker; Iris Shai; Ella Kordysh; Diane E Griffin
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

8.  Factors associated with fatal cases of measles. A retrospective autopsy study.

Authors:  A P Beckford; R O Kaschula; C Stephen
Journal:  S Afr Med J       Date:  1985-12-07

9.  A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles.

Authors:  Fernando P Polack; Scott J Hoffman; Gonzalo Crujeiras; Diane E Griffin
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

10.  Alterations in immune responsiveness in acute measles and chronic post-measles chest disease.

Authors:  H M Coovadia; A Wesley; L G Henderson; P Brain; G H Vos; A F Hallett
Journal:  Int Arch Allergy Appl Immunol       Date:  1978
View more
  1 in total

1.  Human leukocyte antigen and interleukin 2, 10 and 12p40 cytokine responses to measles: is there evidence of the HLA effect?

Authors:  Inna G Ovsyannikova; Jenna E Ryan; Robert M Jacobson; Robert A Vierkant; V Shane Pankratz; Gregory A Poland
Journal:  Cytokine       Date:  2007-01-17       Impact factor: 3.861

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.